Antioxidant Activity of Solenostemon monostachyus (P. Beauv.) Briq. in Induced Rats

Aim: Solenostemon monostachyus (P.Beauv.) Briq.(SE) is the object of our investigation test the mechanism of its anti-oxidative action to further establish its anti-sickling properties..

Sample: To correlate hematological parameters and antioxidant activities with the presence induced hemolytic anemia in female rats to validate other screening parameters.

Place and Duration of Study: The study as carried out in the covenant university animal house and biochemistry laboratory, department of biological sciences, covenant university. sample: the animals were obtained from the Institute for advanced medical research and training (IMRAT), college of medicine, UCH, Orita-mefa, Ibadan, Oyo state and allowed to acclimatize under a 12-hour light/dark cycle for 3 weeks prior to the commencement of the study between January 2015 and February 2015.

Methodology: 2-Butoxyethanol was used to induce hemolytic anemia resembling that of sickle cell disease. The methanolic extract of the leaves was orally administered for 5 days at 150 mg/kg, 200 mg/kg and 250 mg/kg of body weight doses to determine the antioxidant activities and some hematological indices of plasma in the kidney, spleen and liver of 2-butoxyethanol hemolytic-induced rats. Sample: we used 49 Wistar albino rats (49 female; weight: 95-120 g). Hematological examination (PCV, MCV, RBCs, and hemoglobin [Hb] count) and sICAM levels was done besides antioxidant activities (bilirubin, glutathione, superoxide dismutase, TBARS and peroxidase). Weight of the animals was also calculated.

Results: The results were analyzed using ANOVA. The result of the oxidative stress markers showed that SOD, TBARS and peroxidase were insignificant (P>0.05) in the kidney, liver and spleen of all the rats while GSH in the kidney and liver insignificantly high in the SM-treated rats while GSH in the spleen was significantly increased in SM-150 (7.67±2.19) compared to control.

Conclusion: These doses have shown that they can be used alongside other drugs to alleviate oxidative stress in hemolytic anemic related diseases such as sickle cell disease.

These predictors, however, need further work to validate reliability.